Wedbush Securities’s Compass Therapeutics CMPX Stock Holding History

Wedbush Securities’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-43,444	Closed	-$142K	–	1080
2023 Q1	$142K	Buy	+43,444	New	+$171K	0.01%	985

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wedbush Securities's CMPX Position: Q2 2023 in Review

Wedbush Securities sold out of Compass Therapeutics (CMPX) in Q2 2023, closing a stake of 43,444 shares — an estimated $142K sold.

Wedbush Securities first reported a position in CMPX in Q1 2023 and held it in 1 quarter. The position peaked at $142K in Q1 2023. 73 funds tracked by Wall St. Rank hold CMPX as of Q2 2023.

Wedbush Securities reported no remaining Compass Therapeutics position as of Q2 2023 after selling out during the quarter.
Wedbush Securities sold 43,444 Compass Therapeutics shares in Q2 2023, an estimated $142K.
Wedbush Securities first reported a position in Compass Therapeutics in Q1 2023 and held it in 1 quarter.
Wedbush Securities's Compass Therapeutics position peaked at $142K in Q1 2023.
73 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2023.

Based on Wedbush Securities's 13F filing for Q2 2023, filed 14 Aug 2023.